Within the framework of the European Commission-funded Horizon Europe funding program, YSU Institute of Pharmacy hosted Associate Professor Dr. Agnieszka Rombel-Bryzek from the Department of Clinical Biochemistry at the Medical Sciences Institute of the University of Opole. She delivered a presentation dedicated to the in vitro studies of the anticancer activity of new compounds.
Dr. Rombel-Bryzek’s research holds significant potential in the discovery and development of novel anticancer drugs. In her lecture, the speaker discussed the effects of both natural and synthetic compounds on the biological activity of human cells, with particular emphasis on cytotoxic compounds that may contribute to the destruction of cancer cells. Her scientific studies also encompass the evaluation of diverse compounds for their antioxidant, anti-inflammatory, and anticancer properties.
The presentation addressed the methodology of testing cell cultures, which allows for the assessment of the biological activity of new compounds. The crucial role of in vitro studies prior to initiating clinical trials was especially highlighted, as these studies enable the early identification of promising compounds and facilitate the analysis of their effects at the cellular level.
Throughout her scientific career, Dr. Rombel-Bryzek has authored 29 research articles covering various aspects of the biological activity of different compounds.
The presentation served as a new stimulus for specialists engaged in innovative approaches to anticancer treatment. The event once again confirmed that scientific collaboration and international research experience play a vital role in the advancement of medicine and pharmacy.
